-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the new coronary pneumonia virus (COVID-19) spreading in countries around the world, the outcome of COVID-19 infection in patients with specific diseases has attracted widespread attention.
study was designed to investigate the timing of COVID-19 infection in patients with rheumatism and musculoskeletal disease during the COVID-19 pandemic.
researchers used a multi-center, electronic health record network (TriNetX) to conduct a cohort study of patients with rheumatism and musculoskeletal disease diagnosed with COVID-19 infection, comparing the initial 90 days of the pandemic (early queue) with the outcome of the patients in the next 90 days (late queue) (prognosis within 30 days after diagnosis of COVID-19, including hospitalization, intensive care, trachea intestion, kidney failure, and death).
COVID-19 infection was diagnosed over a six-month study period, which included 8,540 patients diagnosed with COVID-19 with rheumatoid and musculoskeletal muscle disease, including 2,811 in the early queue and 5,729 in the late queue.
The combined prognostic cumulative rate of early and late queues: A total exposure score matching analysis; B inpatient sub-group analysis In the exposure score matching analysis, the risk of hospitalization of patients with late-stage queue was lower than that of early queue (32.4% vs. 45.4%; relative risk was 0.71,95% CI 0.67-0.76).
terminally ill patients entered intensive care (7.9% vs 14.3%; RR 0.56), instrumental aeration (3.6% vs 9.1%; 0.39), acute kidney injury (13.8%) vs 20.7%; 0.66), renal replacement therapy (0.6% vs 1.2%; 0.53) and death (4.5% vs 9.3%; 0.48) were also lower risk than in the early queue.
in the subgroup analysis of hospitalized patients, the combined prognosis risk of late-stage cohort patients being admitted to intensive care units, mechanical aeration and death was also lower than that of early cohorts (30.7% vs. 41.3%; RR 0.74).
the study showed that the risk of adverse prognostics after infection with the new coronary pneumonia virus in patients with rheumatoid and musculoskeletal disease improved over time, but the risk of adverse outcomes remained high.
